Skip to main content

Press releases

Archive

Progress in clinical development for Alzheimer´s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator

Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease

Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator

Upcoming events

LSX World Congress USA preview

LSX World Congress USA

SEPTEMBER 15-17, 2025

SACHS 25th Annual Biotech in Europe Forum preview

SACHS 25th Annual Biotech in Europe Forum

OCTOBER 8-9, 2025

AAO 2025 preview

AAO 2025

OCTOBER 17-20, 2024

BIO-Europe 2025

NOVEMBER 3-5, 2024

LSX Inv€$tival Showcase preview

LSX Inv€$tival Showcase

NOVEMBER 17, 2025

Ophthalmology Innovation Summit XV preview

Ophthalmology Innovation Summit XV

NOVEMBER 21-22, 2025

In the news

Archive

Drug Discovery News

An anti-amyloid drug for blindness

The Medicine Maker

A small molecule drug candidate for Alzheimer’s treatment

SCRIP Asks

What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

Multimedia

GAL-101 FOR THE TREATMENT OF DISEASES OF THE EYE